Company Profile

We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic, virus-specific T cell (VST) therapies to treat or prevent devastating viral diseases. Our innovative and proprietary VST therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the devastating consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. To date, we have generated five innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses, the most advanced of which has successfully completed a proof-of-concept trial across five viruses and is entering pivotal trials.
April 6, 2020
AlloVir Appoints Ugo Capolino Perlingieri Head of Europe and Middle East Operations
AlloVir Appoints Ugo Capolino Perlingieri Head of Europe and Middle East Operations
March 26, 2020
European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
Viralym-M recently received EMA PRIME and U.S. FDA RMAT designations
March 23, 2020
AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
AlloVir Expands Research to Discover and Develop Allogeneic, Virus-Specific T-Cell Therapies for COVID-19
February 19, 2020
AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference  
AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference
February 12, 2020
AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet